NIH Funds First Step Towards Advancing ATTR Amyloidosis Drug Development
The NIH has awarded the Amyloidosis Research Consortium $40,000 to support the organization's Amyloidosis Forum meeting on "Advancing Drug Development in ATTR Amyloidosis in an Evolving Treatment Landscape." Formed in 2019, The Amyloidosis Forum (https://amyloidosisforum.org) has been developed through a...
ARC has created a new Patient Advisory Committee to impact the future of amyloidosis treatment and care. As a patient led organization, our team at ARC recognizes the value and importance of engaging and understanding the experiences of patients and...
Advocating for Amyloidosis Patients & Families at the US Congress
ARC participated in the 2023 Rare Disease Week proceedings organized by the EveryLife Foundation alongside five amyloidosis patient and family advocates and over 600 other rare disease advocates. [caption id="attachment_6173" align="aligncenter" width="900"] Amyloidosis patient advocates and ARC staff with other...
ARC in the Field: Global Genes Health Equity Summit 2022
Special Report by: Dr. Lauren Edgar, DNP, RN, MSN-Ed., FNP Associate Director of Clinical Affairs and Education, Amyloidosis Research Consortium The 2nd Annual Global Genoese Rare Health Equity Summit in partnership with the Rare Disease Diversity Coalition took place...
ARC & ASPIRE: Partnerships for Patient-Centric Change
Earlier this month ARC announced the launch of ASPIRE: Amyloidosis Stakeholder Partnerships for Impact, Reach, & Equity. This initiative, independently facilitated and governed by ARC, brings together 10 different biotech & pharmaceutical companies committed to making a real impact in...
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC Talks webinar, amyloidosis cardiologist, Dr. Mazen Hanna discusses the function of implantable, electronic devices in cardiac management of amyloidosis patients.
Dr. Hanna provides clarity about which devices exist to assist patients, and the role they serve in heart maintenance. This includes devices for atrial fibrillation management, such as a watchman device, in addition to the indications for a pacemaker or ICD device.
Original Presentation Date:
February 08, 2024
Key Webinar Highlights:
0:00 — Introduction
3:18 — Start of presentation
4:27 — Atrial fibrillation diagram
6:56 — Atrial fibrillation in cardiac amyloidosis
10:02 — Atrial fibrillation: anticoagulation
12:06— Transesophageal echocardiogram (TEE)
13:13 — Intracardiac thrombosis in cardiac amyloidosis
16:08 — CAA occlusion
19:00 — Atrial fibrillation ablation
20:54 — Atrial fibrillation rate control
21:59 — Atrial fibrillation rhythm control
23:06 — Conduction
25:38 — How a pacemaker works
27:57 — Impact of RV pacing on outcomes in ATTR cardiac amyloidosis
28:29 — Cardiac resynchronization therapy in ATTR cardiac amyloidosis
30:17 — Ventricular Arrythmias in cardiac amyloidosis
31:37 — Primary prevention ICD in ATTR cardiac amyloidosis
32:41 — Standard protocol
33:52 — Guidelines for defibrillators
34:37 — MEMs based pressure sensor for monitoring pulmonary artery pressures